Powder: -20°C for 3 years | In solvent: -80°C for 1 year
C-ABL-IN-5, a selective c-Abl inhibitor, exhibits neuroprotective properties and has favorable characteristics including blood-brain barrier permeability, metabolic stability, and pharmacokinetic profiles. When labeled with [18F] (compound [18F]3), C-ABL-IN-5 serves as a tracer in positron emission tomography (PET) scans to assess disease-modifying effects, particularly in research on neurodegenerative conditions like Parkinson's disease (PD) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | C-ABL-IN-5, a selective c-Abl inhibitor, exhibits neuroprotective properties and has favorable characteristics including blood-brain barrier permeability, metabolic stability, and pharmacokinetic profiles. When labeled with [18F] (compound [18F]3), C-ABL-IN-5 serves as a tracer in positron emission tomography (PET) scans to assess disease-modifying effects, particularly in research on neurodegenerative conditions like Parkinson's disease (PD) [1]. |
Molecular Weight | 341.35 |
Formula | C19H17F2N3O |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
c-ABL-IN-5 Angiogenesis Cytoskeletal Signaling Tyrosine Kinase/Adaptors Bcr-Abl inhibitor inhibit